US02043Q1076 - Common Stock - After market: 219.64 0 (0%)
NASDAQ:ALNY (12/6/2022, 7:21:00 PM)-6.56 (-2.9%)
|GICS Sector||Health Care|
|Earnings (Last)||10-27 2022-10-27/bmo||Earnings (Next)||02-08 2023-02-08|
|Ins Owners||0.24%||Inst Owners||104.94%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1,665 full-time employees. The company went IPO on 2004-05-28. The company is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS 02142
CEO: John M. Maraganore
/PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), empresa líder em terapias de RNAi, acaba de anunciar que a Agência Nacional de Vigilância...
Alnylam Pharmaceuticals Inc. said it’s stopping work on a treatment for a rare eye disease because of a new US drug-pricing law with the potential to limit how much it could charge for the medication in the future.
Here you can normally see the latest stock twits on ALNY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.